Cumberland Pharmaceuticals Inc. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
Cumberland Pharmaceuticals Inc. (CPIX) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of -$0.08 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2026-08-07
- Cumberland Pharmaceuticals Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2026-06-30 was -$0.08, a 153.33% decline year-over-year.
- Cumberland Pharmaceuticals Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2025-06-30 was $0.15.
- Cumberland Pharmaceuticals Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Cumberland Pharmaceuticals Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Cumberland Pharmaceuticals Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Cumberland Pharmaceuticals Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2021 was $0.13, a 38.10% decline from fiscal 2020.
- Cumberland Pharmaceuticals Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2020 was $0.21, a 43.24% decline from fiscal 2019.
- Cumberland Pharmaceuticals Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2019 was $0.37, a 54.17% increase from fiscal 2018.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$0.08 10-Q · filed 2026-08-07 | -$0.11 10-Q · filed 2026-08-07 | |||
| 2025-06-30 | $0.15 10-Q · filed 2026-08-07 | $0.41 10-Q · filed 2026-08-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-13 | $0.00 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $0.00 10-K · filed 2023-03-13 | $0.00 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $0.00 10-K · filed 2023-03-13 | $0.00 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | $0.00 10-K · filed 2023-03-13 | ||||
| 2021-12-31 | $0.03 10-K · filed 2023-03-13 | $0.13 10-K · filed 2023-03-13 | |||
| 2021-09-30 | $0.03 10-K · filed 2023-03-13 | $0.10 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $0.03 10-K · filed 2023-03-13 | $0.07 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $0.03 10-K · filed 2023-03-13 | ||||
| 2020-12-31 | $0.06 10-K · filed 2022-03-11 | $0.21 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $0.05 10-K · filed 2022-03-11 | $0.15 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $0.05 10-K · filed 2022-03-11 | $0.10 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | $0.05 10-K · filed 2022-03-11 | ||||
| 2019-12-31 | $0.16 10-K · filed 2021-03-12 | $0.37 10-K · filed 2022-03-11 | |||
| 2019-09-30 | $0.09 10-K · filed 2021-03-12 | $0.21 10-Q · filed 2020-11-13 | |||
| 2019-06-30 | $0.05 10-K · filed 2021-03-12 | $0.12 10-Q · filed 2020-08-14 | |||
| 2019-03-31 | $0.08 10-K · filed 2021-03-12 | ||||
| 2018-12-31 | $0.07 8-K · filed 2020-12-10 | $0.24 10-K · filed 2021-03-12 | $0.25 8-K · filed 2020-12-10 | ||
| 2018-09-30 | $0.05 8-K · filed 2020-12-10 | ||||
| 2018-06-30 | $0.06 8-K · filed 2020-12-10 | ||||
| 2018-03-31 | $0.06 8-K · filed 2020-12-10 | ||||
| 2017-12-31 | $0.30 8-K · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |